FasL Cancer Research Results

FasL, Fas ligand: Click to Expand ⟱
Source:
Type:
Fas ligand (FasL) is a protein that plays a crucial role in the regulation of the immune system and programmed cell death, also known as apoptosis. In the context of cancer, FasL has been found to have both tumor-promoting and tumor-suppressing effects.
FasL is upregulated in melanoma, colon.
FasL: tumor suppressing effect on Breast and Lung cancer.

FasL inhibitors, which block the interaction between Fas and FasL, have been shown to enhance the effectiveness of chemotherapy and immunotherapy
Scientific Papers found: Click to Expand⟱
6491- Nimb,    Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells
- Review, PC, NA
eff↑, Drug loading and encapsulation efficiency of Nim-nano were 5.25%±1.12% and 55.67%±12.42%, respectively.
uPA↓, Nim reduces the movement and invasive potential of MCF-7 and MDA-MB-231 cell lines by downregulation of uPA, uPAR, chemokines, pEGFR, VEGFR, NFкB, IKKα, IKKβ, MMP2, and MMP9 and upregulation of TIMP2.
uPAR↓,
p‑EGFR↓,
VEGFR1↓,
NF-kB↓,
IKKα↓,
MMP2↓,
MMP9↓,
TIMP2↑,
TumCP↓, Nim also inhibits cell propagation and cell survival by downregulation of IGF1R–Akt–ERK signaling, which accumulates G0/G1 cells and downregules cyclin protein expression
IGFR↓,
Akt↓,
ERK↓,
TumCCA↓,
BAX↑, increases levels of proapoptotic proteins Bax, Bad, FasL, TRAIL, FADDR, and cytochrome C
BAD↑,
FasL⇅,
Cyt‑c↑,
EPR↑, enhanced effect of Nim-nano might have been due to increased cellular uptake and less efflux by Pgp pumps with the same mode of action.


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Akt↓, 1,   BAD↑, 1,   BAX↑, 1,   Cyt‑c↑, 1,   FasL⇅, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ERK↓, 1,   IGFR↓, 1,  

Migration(tgid=13) ⓘ

MMP2↓, 1,   MMP9↓, 1,   TIMP2↑, 1,   TumCP↓, 1,   uPA↓, 1,   uPAR↓, 1,   VEGFR1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

p‑EGFR↓, 1,   EPR↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IKKα↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

p‑EGFR↓, 1,  
Total Targets: 21

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: FasL, Fas ligand
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:593  State#:%  Dir#:3
  wNotes=on  sortOrder:rid,rpid

 

Home Page